Trial Profile

A multicenter, randomized, double-blind, placebo-controlled, parallel group, phase III clinical trial of Insugin (Liquid Insulin Mouth Rinse) for Type 2 diabetes patients

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 05 Jul 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Jun 2019 According to an EastGate Biotech media release, the company has filed an application with the Drug Regulatory Authority of Pakistan (DRAP) and Ministry of National Health Services to initiate a Phase III clinical study for Insugin. The application requests the dosing of 200 Type 2 diabetic patients in order to achieve statistically significant results for regulatory approval of Insugin in Pakistan. EastGate is considering dosing as many as 500 patients for inclusion in the study.
20 Jun 2019 New trial record
15 May 2019 According to an EastGate Biotech media release, this study will be conducted in joint venture with Genome Pharma/Origin Pharma.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com